eltrombopag choline · Teva Pharms Inc · NDA 216774
Alvaiz
Earliest generic entry, as listed · earliest of 4 marketed strengths
5 Nov 2038
Blocked by patent: US 11072586.
Listed patents · 1 unexpired
3 Orange Book listing rows for 1 patent. FDA lists a patent once for each use code, and lists its pediatric extension as a separate row.
| Patent | Claims | Expires |
|---|---|---|
| US 11072586 | drug substance, drug product, use U-3936, U-3937, U-3938 | 5 Nov 2038 |
| US 11072586 listing row | drug substance, drug product, use U-3936 · sets the listed date | 5 Nov 2038 |
| US 11072586 listing row | drug substance, drug product, use U-3937 · sets the listed date | 5 Nov 2038 |
| US 11072586 listing row | drug substance, drug product, use U-3938 · sets the listed date | 5 Nov 2038 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 4
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 216774 · 001 · RLD | tablet, oral | EQ 9MG BASE | 5 Nov 2038 |
| 216774 · 002 · RLD | tablet, oral | EQ 18MG BASE | 5 Nov 2038 |
| 216774 · 003 · RLD | tablet, oral | EQ 36MG BASE | 5 Nov 2038 |
| 216774 · 004 · RLD | tablet, oral | EQ 54MG BASE | 5 Nov 2038 |